Juha Onatsu1, Ritva Vanninen2, Pekka Jäkälä3, Pirjo Mustonen4, Kari Pulkki5, Miika Korhonen6, Marja Hedman6, Henrik Zetterberg7, Kaj Blennow8, Kina Höglund8, Sanna-Kaisa Herukka3, Mikko Taina6. 1. Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland. Electronic address: Juha.Onatsu@kuh.fi. 2. Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland; Department of Clinical Radiology, University of Eastern Finland, Kuopio Finland. 3. Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland; Unit of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. 4. Department of Cardiology, Keski-Suomi Central Hospital, Jyväskylä, Finland. 5. Department of Clinical Radiology and Clinical Chemistry, Kuopio, Finland; Eastern Finland Laboratory Center and Department of Clinical Chemistry, University of Eastern Finland, Kuopio, Finland. 6. Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland. 7. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom; UK Dementia Research Institute, London, United Kingdom. 8. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Abstract
BACKGROUND AND PURPOSE: We studied serum neurofilaments diagnostic value in patients with acute ischemic stroke (AIS) or TIA and evaluated any correlation with symptom severity, cerebral infarction volume, aetiology, and clinical outcome. METHODS: One hundred and thirty-six patients (101 with AIS, and 35 with TIA) were included. Acute-phase serum neurofilament light chain (sNfL) was analyzed with a novel ultrasensitive single molecule array (Simoa). Cerebral infarction volume was measured from brain computed tomography in the subacute phase (>2 days). Stroke aetiology was defined by trial of ORG 10172 in acute stroke treatment classification, severity by National Institute of Health stroke scale (NIHSS) and the degree of disability by the Modified Rankin Scale (mRS) after 90 days. RESULTS: sNfL was markedly higher in patients with AIS (89.5 pg/mL [IQR: 44.7-195.3]) than with TIA (25.2 pg/mL [IQR: 14.6-48.0]), P= <.001), also after adjusting for age, NIHSS, and stroke volume (P= .003). In receiver operating characteristic analysis, sNfL concentration greater than or equal to 49 pg/mL proved to be the best cut-off value to differentiate between patients with stroke and those with TIA (sensitivity of 73% and specificity of 80%). sNfL concentration significantly correlated with cerebral infarction volume (r = .413, P= <.001), this association remained significant after adjusting for established predictors (P= .019). Patients with AIS due to cardioembolism or large artery atherosclerosis had the highest sNfL concentrations. NIHSS on admission (r = .343, P = <.001) and mRS scores after 3 months (r = .306, P = .004) correlated with sNfL concentration, however functional outcome 3 months after stroke was not associated with sNfL after adjusting for potential confounders. CONCLUSIONS: Cases with stroke were distinguishable from those with TIA following the determination of sNfL in the blood samples. The presence and amount of axonal damage estimated by sNfL correlated with the final cerebral infarction volume but was not predictive of degree of disability.
BACKGROUND AND PURPOSE: We studied serum neurofilaments diagnostic value in patients with acute ischemic stroke (AIS) or TIA and evaluated any correlation with symptom severity, cerebral infarction volume, aetiology, and clinical outcome. METHODS: One hundred and thirty-six patients (101 with AIS, and 35 with TIA) were included. Acute-phase serum neurofilament light chain (sNfL) was analyzed with a novel ultrasensitive single molecule array (Simoa). Cerebral infarction volume was measured from brain computed tomography in the subacute phase (>2 days). Stroke aetiology was defined by trial of ORG 10172 in acute stroke treatment classification, severity by National Institute of Health stroke scale (NIHSS) and the degree of disability by the Modified Rankin Scale (mRS) after 90 days. RESULTS:sNfL was markedly higher in patients with AIS (89.5 pg/mL [IQR: 44.7-195.3]) than with TIA (25.2 pg/mL [IQR: 14.6-48.0]), P= <.001), also after adjusting for age, NIHSS, and stroke volume (P= .003). In receiver operating characteristic analysis, sNfL concentration greater than or equal to 49 pg/mL proved to be the best cut-off value to differentiate between patients with stroke and those with TIA (sensitivity of 73% and specificity of 80%). sNfL concentration significantly correlated with cerebral infarction volume (r = .413, P= <.001), this association remained significant after adjusting for established predictors (P= .019). Patients with AIS due to cardioembolism or large artery atherosclerosis had the highest sNfL concentrations. NIHSS on admission (r = .343, P = <.001) and mRS scores after 3 months (r = .306, P = .004) correlated with sNfL concentration, however functional outcome 3 months after stroke was not associated with sNfL after adjusting for potential confounders. CONCLUSIONS: Cases with stroke were distinguishable from those with TIA following the determination of sNfL in the blood samples. The presence and amount of axonal damage estimated by sNfL correlated with the final cerebral infarction volume but was not predictive of degree of disability.
Authors: Chi Ho Wai; Jessica Jin; Marek Cyrklaff; Christel Genoud; Charlotta Funaya; Julia Sattler; Aleksandra Maceski; Stephanie Meier; Sabine Heiland; Michael Lanzer; Friedrich Frischknecht; Jens Kuhle; Martin Bendszus; Angelika Hoffmann Journal: Sci Rep Date: 2022-06-24 Impact factor: 4.996
Authors: Juha Onatsu; Ritva Vanninen; Pekka JÄkÄlÄ; Pirjo Mustonen; Kari Pulkki; Miika Korhonen; Marja Hedman; Kina HÖglund; Kaj Blennow; Henrik Zetterberg; Sanna-Kaisa Herukka; Mikko Taina Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Tania F Gendron; Mohammed K Badi; Michael G Heckman; Karen R Jansen-West; George K Vilanilam; Patrick W Johnson; Alexander R Burch; Ronald L Walton; Owen A Ross; Thomas G Brott; Timothy M Miller; James D Berry; Katharine A Nicholson; Zbigniew K Wszolek; Björn E Oskarsson; Kevin N Sheth; Lauren H Sansing; Guido J Falcone; Brett L Cucchiara; James F Meschia; Leonard Petrucelli Journal: Sci Transl Med Date: 2020-11-11 Impact factor: 19.319
Authors: Helle H Nielsen; Catarina B Soares; Sofie S Høgedal; Jonna S Madsen; Rikke B Hansen; Alex A Christensen; Charlotte Madsen; Bettina H Clausen; Lars Henrik Frich; Matilda Degn; Christian Sibbersen; Kate L Lambertsen Journal: Front Neurol Date: 2020-06-11 Impact factor: 4.003
Authors: Angela M Boutté; Vivian Hook; Bharani Thangavelu; George Anis Sarkis; Brittany N Abbatiello; Gregory Hook; J Steven Jacobsen; Claudia S Robertson; Janice Gilsdorf; Zhihui Yang; Kevin K W Wang; Deborah A Shear Journal: J Neurotrauma Date: 2020-04-02 Impact factor: 5.269